A former director and CTO of a major biotech firm shares the moment profit motives superseded the mission to conquer aging. The narrative details an unexpected pivot from longevity research, using Geron Corporation's shift toward cancer treatment as a stark example of corporate influence over foundational scientific discovery. This account offers a sobering perspective on the roadblocks facing true anti-aging breakthroughs.
#AgingResearch #BiotechIndustry #PharmaExposed #Telomeres #LongevityScience #ScientificEthics #CTOShow #DrBillAndrews